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Summary
The mechanistic Target of Rapamycin Complex 1 (mTORC1) is a major regulator of eukaryotic 
growth that coordinates anabolic and catabolic cellular processes with inputs such as growth 
factors and nutrients, including amino acids1–3. In mammals, arginine is particularly important and 
promotes diverse physiological effects including immune cell activation, insulin secretion, and 
muscle growth, largely through activation of mTORC14–7. Arginine activates mTORC1 upstream 
of the Rag GTPases8, through either the lysosomal amino acid transporter SLC38A9 or the 
GATOR2-interacting CASTOR1 (Cellular Arginine Sensor for mTORC1)9–12. However, the 
mechanism by which the mTORC1 pathway detects and transmits the arginine signal has been 
elusive. Here, we present the 1.8 Å crystal structure of arginine-bound CASTOR1. Homodimeric 
CASTOR1 binds arginine at the interface of two ACT domains, enabling allosteric control of the 
adjacent GATOR2-binding site to trigger dissociation from GATOR2 and the downstream 
activation of mTORC1. Our data reveal that CASTOR1 shares substantial structural homology 
with the lysine-binding regulatory domain of prokaryotic aspartate kinases, suggesting that the 
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mTORC1 pathway exploited an ancient amino-acid-dependent allosteric mechanism to acquire 
arginine sensitivity. Together, these results establish a structural basis for arginine sensing by the 
mTORC1 pathway and provide insights into the evolution of a mammalian nutrient sensor.
To understand the molecular mechanisms through which CASTOR1 detects arginine and 
signals its presence to mTORC1, we determined the crystal structure of arginine-bound 
CASTOR1 to 1.8 Å resolution (Extended Data Table 1). CASTOR1 forms a rod-shaped 
homodimer, with the monomers associated in a side-by-side manner and rotated 180° with 
respect to each other (Fig. 1a). While sequence analysis of CASTOR1 predicted the 
presence of two ACT (Aspartate Kinase, Chorismate mutase, TyrA) domains12,13, the 
structure reveals that each monomer actually contains four tandem ACT domains. ACT1 
displays the canonical βαββαβ ACT domain topology14,15, whereas ACT3 and ACT4 each 
lack the final β-strand and ACT2 contains two additional β-strands (Fig. 1a, Extended Data 
Fig. 1a).
The dimerization interface buries ~950 Å2 of surface area at the intersection of α1 and α5, 
from ACT1 and ACT3, respectively (Fig. 1b). Four inward facing isoleucines (Ile28 and 
Ile202) form the hydrophobic core of the symmetrical interface, flanked on each side by 
tyrosine-histidine pairs (His25 and Tyr207) that form both pi-stacking and hydrogen-bond 
contacts with the opposing monomer (Fig. 1b). To understand the importance of 
dimerization for CASTOR1 function, we generated constitutively monomeric mutants of 
CASTOR1 (Y207S and I202E, Fig. 1c). Interestingly, although dimerization is dispensable 
for arginine binding (Extended Data Fig. 2a), these mutants interacted weakly with 
GATOR2 and failed to inhibit mTORC1 signalling in cells (Fig. 1c, Extended Data Fig. 2b), 
indicating that CASTOR1 must be dimeric to robustly inhibit GATOR2 upon arginine 
starvation.
CASTOR1 binds arginine through a narrow pocket at the interface of ACT2 and ACT4, 
distal to the dimerization interface (Fig. 1a, 2a, b). The side-chain of arginine points towards 
a loop connecting β15 and β16 (β15-loop), where the backbone carbonyls of Thr300, 
Phe301, and Phe303 coordinate the guanidinium group of arginine (Fig. 2a). Immediately 
adjacent to the β15-loop, the anionic side-chain of Asp304 forms an additional stabilizing 
salt-bridge with the cationic arginine side-chain (Fig. 2a). On the opposite side of the pocket, 
the hydroxyl side-chain of Ser111 and backbone carbonyl of Val112 in the α3-loop anchor 
the free amine of arginine in place, while the free carboxyl points towards a water-filled 
cavity that separates it from ACT2 (Fig 2a, b). Consistent with a critical role for these 
contacts in arginine sensing by CASTOR1, mutation of either Ser111 or Asp304 (S111A, 
D304A) abolished the arginine binding capacity of CASTOR1 in vitro (Fig. 2c). 
Furthermore, when expressed in HEK-293T cells, these mutants bound constitutively to 
GATOR2 and strongly inhibited mTORC1 signalling even in the presence of arginine (Fig. 
2D).
Together, these data explain the molecular determinants of specificity in the CASTOR1-
arginine interaction. While Ser111 fixes the position of the free amine, the location of the 
β15-loop and Asp304 sets a strict length requirement for the bound ligand (Extended Data 
Fig. 3a). In addition, the positions of the three hydrogen-bond donating nitrogens in the 
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guanidinium group facilitate contacts with both the carbonyl oxygens in the β15-loop and 
the side-chain of Asp304 (Fig. 2a). Finally, the gap behind the free carboxyl group of 
arginine suggests that CASTOR1 can tolerate ligands with modifications to that functional 
group (Fig. 2b). We tested these predictions by interrogating the ability of various arginine 
analogues to disrupt the CASTOR1-GATOR2 interaction in vitro (Fig. 2e, Extended Data 
Fig. 3b). Consistent with our structural analysis, while the carboxy-modified arginine-
methyl ester triggered full dissociation of CASTOR1 from GATOR2, compounds with 
alterations to the guanidium group, α-amine, or side-chain length had no effect.
In addition to the main pocket contacts described above, a highly conserved, glycine-rich 
loop connecting β14 and α7 in ACT4 (“β14-loop”, residues 269–280) wraps over the 
arginine-pocket, fully burying the bound ligand (Fig. 2a, 3a, Extended Data Fig. 1a). The 
β14-loop forms several hydrogen-bonds with arginine through the backbone amides of 
Gly279 and Ile280, as well as the backbone oxygens of Gly274 and Glu277 (Fig. 2a, 3a). 
The ordered conformation of the β14-loop also places it just along the ACT2-ACT4 
interface, enabling it to form several intramolecular contacts with residues in ACT2 (Fig. 
3a). Cys278 hydrogen bonds with the backbones of Val110 and S111 in the α3-loop, while 
Asp276 forms a salt-bridge with Arg126. In addition, Glu277 extends in the opposite 
direction to form another salt-bridge with His175. (Fig. 3a). Thus, the β14-loop facilitates 
the formation of numerous inter-ACT-domain contacts in the presence of arginine. Indeed, 
the arginine and β14-loop contribute ~40% of the total buried surface area in the ACT2-
ACT4 interface of the arginine-bound structure (390 Å2 out of 980 Å2).
The glycine-rich β14-loop is predicted to have a high propensity for disorder, and our 
structure suggests that these inter-ACT-domain contacts could stabilize it in an ordered 
conformation over the bound arginine. Indeed, mutation of key residues in both the β14-loop 
(D276A, E277A, C278A) and the adjacent ACT domains (R126A, H175A) significantly 
reduced the arginine binding capacity of CASTOR1 (Fig. 3b, c), indicating that the inter-
ACT-domain contacts formed by the β14-loop are required for arginine sensing by 
CASTOR1. In addition, we found that the N-terminal (ACT1 and ACT2) and C-terminal 
(ACT3 and ACT4) halves of CASTOR1 associate in both an arginine- and β14-loop-
dependent manner when expressed as separate polypeptides in HEK-293T cells12 (Fig. 3d), 
indicating that arginine likely induces a conformational change in CASTOR1 by stabilizing 
the ACT2-ACT4 interaction.
In addition to CASTOR1, human cells express a related protein, CASTOR2, which shares 
63% sequence identity but does not bind arginine12. Although the regions of CASTOR1 
directly involved in arginine binding are well conserved (Extended Data Fig. 1a), we 
identified residues along the ACT2-ACT4 interface (His108 to Val110) that differ between 
CASTOR1 and CASTOR2 (Extended Data Fig. 4a). Switching these residues of CASTOR1 
with those in CASTOR2 abrogated arginine binding in vitro and converted CASTOR1 to a 
nearly constitutive GATOR2-interactor in cells, resembling CASTOR2 (Extended Data Fig. 
4b–d). Interestingly, these residues immediately precede Ser111 and hydrogen bond with 
Cys278 in the β14-loop (Fig. 3a, Extended Data Fig. 4a), suggesting that their identity may 
be critical for the proper positioning of the α3-loop to enable arginine binding and/or the 
association of ACT2 and ACT4. The corresponding mutation in CASTOR2 
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(108QNI-110HHV) however was not sufficient to confer arginine binding, suggesting that 
additional differences also contribute (Extended Data Fig. 4d).
To understand how arginine induces dissociation of CASTOR1 from GATOR2, we 
identified five highly conserved sites in CASTOR1 required for the interaction with 
GATOR2 (Y118, Q119, D121, E261, D292, Fig. 4a, Extended Data Fig. 1a). Importantly, 
these mutants still bind arginine in vitro and homodimerize when expressed in cells 
(Extended Data Fig. 5a, b). Interestingly, these residues cluster along the surface of the 
ACT2-ACT4 interface, adjacent to but on the opposite face of the protein as the arginine-
binding pocket (Fig. 4b, c). Glu261 and Asp292 are closely linked to the β14-loop, 
separated only by β14 and helix α7, respectively (Fig. 4c). Furthermore, the critically 
important residue Asp121 is buried in the ACT2-ACT4 interface, providing one explanation 
for why the arginine-bound conformation is incompatible with the CASTOR1-GATOR2 
interaction (Fig. 4c).
Together, these results suggest a model where arginine binding orders the glycine-rich β14-
loop to enable the intramolecular association of ACT2 and ACT4 (Fig. 3a–d). This 
association of these domains would alter the positions and exposure of the residues required 
for GATOR2 binding, which also lie along the ACT2-ACT4 interface (Fig. 4a–c), thereby 
triggering the dissociation of CASTOR1 from GATOR2 and the subsequent activation of 
mTORC1 (Fig. 4e).
The observation that CASTOR1 both inhibits mTORC1 signalling and interacts with 
GATOR2 in an arginine-sensitive manner suggests that CASTOR1 may regulate mTORC1 
by inhibiting GATOR2, a mechanism analogous to that of the recently identified leucine 
sensor Sestrin216–19. Using our GATOR2 binding-deficient mutants, we were able to test 
this hypothesis directly. Indeed, in contrast to wild-type CASTOR1, the GATOR2-binding 
deficient YQ118–119AA and D121A mutants both failed to inhibit mTORC1 signalling in 
cells (Fig. 4d). Moreover, due to their ability to dimerize with endogenous CASTOR1, these 
mutants also functioned as dominant negatives, rendering mTORC1 fully resistant to 
arginine starvation (Fig. 4d). Thus, the CASTOR1-GATOR2 interaction is required to signal 
arginine deprivation to mTORC1.
Although defined by their common topology, ACT domains are highly diverse in sequence 
and form a wide range of structural assemblies14,15. Comparison of our structure with other 
ACT domain-containing proteins in the Protein Data Bank (PDB) revealed that CASTOR1 
shares substantial structural homology with the allosteric regulatory domains of bacterial 
Aspartate Kinases (AKs), including those found in E. coli (AKeco) and cyanobacteria 
(AKsyn)20,21 (Fig. 5a, Extended Data Fig. 6a). AKs catalyze the first step of a metabolic 
pathway that synthesizes several amino acids, including lysine, and display allosteric 
feedback inhibition when downstream products bind to the regulatory domains22. 
Interestingly, AKeco binds lysine through pockets that bear striking resemblance to the 
arginine-binding pocket of CASTOR120 (Fig. 5b). Furthermore, AKeco residues Arg305, 
Glu346, and Val347, which correspond to the positions of the critical GATOR2-binding 
residues Glu261, Tyr118, and Gln119, respectively, directly participate in the lysine-
dependent inhibition of the kinase domain in AKeco20 (Fig. Extended Data Fig. 6b). Thus, 
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the overall structure, mode of amino-acid binding, and likely allosteric mechanism of 
CASTOR1 all resemble those found in the regulatory domain of prokaryotic AKs.
These similarities suggest that CASTOR1 shares an evolutionary origin with prokaryotic 
AKs. Interestingly, AKs are found throughout bacteria, archaea, and many eukaryotic 
lineages, but were lost prior to the emergence of metazoa, while CASTOR1 homologues are 
only present in metazoa (Fig. 5c). Thus, in order to acquire arginine sensitivity in early 
multicellular animals, the mTORC1 pathway may have taken advantage of this more 
ancient, lysine-sensitive regulatory mechanism (Fig. 5d). This exploitation of a pre-existing 
allosteric module is analogous to the models proposed for the evolution of hormone-receptor 
signalling23 and yeast MAP kinases24, and may enable the more rapid incorporation of novel 
signalling responses into existing pathways25.
Together, our results provide a structural basis for arginine sensing by the mTORC1 
pathway. Furthermore, our data using arginine analogues suggests that our structure may be 
useful for predicting compounds that can modulate arginine sensing by CASTOR1 in vivo. 
As deregulation of mTORC1 is common in human diseases, including cancer26,27, the 
identification of novel pharmacological regulators of mTORC1 activity is of particular 
interest.
Methods
Materials
Reagents were obtained from the following sources: HRP-labeled anti-rabbit secondary 
antibody from Santa Cruz Biotechnology; antibodies to phospho-T389 S6K1, S6K1, Mios 
and the FLAG epitope from Cell Signaling Technology; antibodies to the HA epitope from 
Bethyl laboratories; antibody to raptor from Millipore. All antibodies used have been 
published previously12,19. FLAG-M2 affinity gel and amino acids from Sigma Aldrich; 
RPMI without leucine, arginine, or lysine from Pierce; DMEM from SAFC Biosciences; 
XtremeGene9 and Complete Protease Cocktail from Roche; Inactivated Fetal Calf Serum 
(IFS) from Invitrogen; [3H]-labeled arginine from American Radiolabeled Chemicals.
Protein production and purification
Full-length, codon-optimized human CASTOR1 was N-terminally fused with a human 
rhinovirus 3C protease–cleavable His10-Arg8-ScSUMO tag and cloned into a PET-Duet-1 
bacterial expression vector. This vector was transformed into Escherichia coli LOBSTR 
(DE3) cells (Kerafast)28. Cells were grown at 37 °C to 0.6 OD, then protein production was 
induced with 0.2 mM IPTG at 18 °C for 12–14 h. Cells were collected by centrifugation at 
6,000g, resuspended in lysis buffer (50 mM potassium phosphate, pH 8.0, 500 mM NaCl, 30 
mM imidazole, 3 mM β-mercaptoethanol (βME) and 1 mM PMSF) and lysed with a cell 
disruptor (Constant Systems). The lysate was cleared by centrifugation at 10,000g for 20 
min. The soluble fraction was incubated with Ni-Sepharose 6 Fast Flow beads (GE 
Healthcare) for 30 min on ice. After washing of the beads with lysis buffer, the protein was 
eluted in 250 mM imidazole, pH 8.0, 150 mM NaCl and 3 mM βME. The Ni eluate was 
diluted 1:1 with 10 mM potassium phosphate, pH 8.0, 0.1 mM EDTA and 1 mM 
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dithiothreitol (DTT), and was subjected to cation-exchange chromatography on a 5 ml SP 
sepharose fast flow column (GE Healthcare) with a linear NaCl gradient. The eluted 
CASTOR1 was then incubated with 3C protease and dialyzed overnight at 4 °C into 10 mM 
potassium phosphate, pH 8.0, 150 mM NaCl, 0.1 mM EDTA and 1 mM DTT, followed by a 
second cation-exchange chromatography run on an SP sepharose fast flow column (GE 
Healthcare) with a linear NaCl gradient. The protein was further purified via size-exclusion 
chromatography on a Superdex S200 16/60 column (GE Healthcare) equilibrated in running 
buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1 mM EDTA and 1 mM DTT). 
Selenomethionine (SeMet)-derivatized CASTOR1 was prepared as described previously29 
and purified as the native version, except that the reducing-agent concentration (βME and 
DTT) was 5 mM in all buffers.
Crystallization
Purified CASTOR1 was concentrated to 6 mg/ml and incubated in 2 mM arginine for >1 
hour prior to setting crystal trays. Crystals were grown at 18 °C by hanging-drop vapor 
diffusion with 1 μl of protein at 6 mg/ml mixed with an equal volume of reservoir solution 
containing 0.1 M sodium acetate pH 5.0, 0.25 M ammonium acetate, and 22.5% PEG 3350. 
Selenomethionine-derivatized CASTOR1 crystallized in 0.1 M BIS-TRIS pH 5.6, 0.25 M 
ammonium acetate, and 22.5% PEG3350. Crystals were cryoprotected in mother liquor 
supplemented with 20% (v/v) ethylene glycol.
Data collection and structure determination
Data collection was performed at the Advanced Photon Source end station 24-IDC at 
Argonne National Lab, at 100 K. All data-processing steps were carried out with programs 
provided through SBgrid30. Data reduction was performed with HKL200031. A complete 
native dataset was collected to 1.8 Å (at wavelength 0.9792 Å) and a complete SeMet 
dataset, at the selenium peak wavelength (0.9792 Å), was collected to 2.2 Å. The phase 
problem was solved using single-wavelength anomalous dispersion (SAD) and selenium 
positions were determined in HYSS, run as part of the PHENIX AutoSol program32, for the 
SeMet dataset (space group P21, 4 molecules per asymmetric unit). An interpretable 2.2 Å 
experimental electron density map was obtained, and manual model building was carried out 
in Coot33. Subsequent refinement was carried out with the superior 1.8 Å native data set 
using phenix.refine to a final Rwork/Rfree of 17.2%/20.4%. Ramachandran statistics in the 
final model are 99% favored, 1% allowed, and 0% outlier.
Structural analysis
Protein-protein and protein-ligand interfaces were analyzed using PDBePISA34. NCBI’s 
Vector Alignment Search Tool (VAST)35 was used to identify structurally related proteins in 
the PDB. The multiple sequence alignment (MSA) was generated in Jalview36 with the T-
Coffee alignment algorithm37. Sequences of CASTOR1 homologues were obtained via 
NCBI BLAST searches38. All structure figures were made in PyMol39.
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Cell lysis and immunoprecipitation
Cells were rinsed one time with ice-cold PBS and immediately lysed with Triton lysis buffer 
(1% Triton, 10 mM β-glycerol phosphate, 10 mM pyrophosphate, 40 mM Hepes pH 7.4, 2.5 
mM MgCl2 and 1 tablet of EDTA-free protease inhibitor [Roche] (per 25 ml buffer). The 
cell lysates were cleared by centrifugation at 13,000 rpm at 4°C in a microcentrifuge for 10 
minutes. For anti-HA-immunoprecipitations, the magnetic anti-HA beads (Pierce) were 
washed 3 times with lysis buffer. 30 μl of a 50/50 slurry of the affinity gel was then added to 
clarified cell lysates and incubated with rotation for 1 hour at 4°C. Following 
immunoprecipitation, the beads were washed 4 times with lysis buffer containing 500 mM 
NaCl. Immunoprecipitated proteins were denatured by the addition of 50 μl of sample buffer 
and boiling for 5 minutes as described40, resolved by 8%–16% SDS-PAGE, and analyzed by 
immunoblotting.
For co-transfection experiments in HEK-293T cells, 2.5 million cells were plated in 10 cm 
culture dishes. Twenty-four hours later, cells were transfected using the polyethylenimine 
method41 with the pRK5-based cDNA expression plasmids indicated in the following 
amounts: 50 ng CASTOR1-HA (wild-type or mutant), 50 ng CASTOR1-FLAG, 1 μg HA-
metap2, or 2 ng S6K. For in vitro dissociation experiments, 50 ng of wild-type CASTOR1-
HA was transfected into HEK-293T cells. The total amount of plasmid DNA in each 
transfection was normalized to 5 μg with empty pRK5. 36–48 hours after transfection, cells 
were lysed as described above.
For experiments that required amino acid starvation or restimulation, cells were treated as 
previously described42. Briefly, cells were incubated in arginine free RPMI for 50 minutes 
and then restimulated with 500 μM arginine for 10 minutes.
Arginine binding assay
5 million HEK-293T cells were plated in a 15 cm plate four days prior to the experiment. 
Twenty-four hours after plating, the cells were transfected via the polyethylenimine method 
with the pRK5-based cDNA expression plasmids indicated in the figures in the following 
amounts: 15 μg FLAG-Rap2A, 500 ng FLAG-CASTOR1 (wild-type or mutant). The total 
amount of plasmid DNA in each transfection was normalized to 15 μg total DNA with 
empty-PRK5. Forty-eight hours after transfection cells were lysed as previously described. 
If multiple samples of the same type were represented in the experiment, the cell lysates 
were combined, mixed, and evenly distributed amongst the relevant tubes.
Anti-FLAG beads were blocked by rotating in 1 μg/μl bovine serum albumin (BSA) for 20 
minutes at 4 °C, then washed twice in lysis buffer and resuspended in an equal volume of 
lysis buffer. 30 μl of bead slurry was added to each of the clarified cell lysates and incubated 
as previously described. Post-IP, the beads were washed as previously and incubated for one 
hour on ice in cytosolic buffer (0.1% Triton, 40 mM HEPES pH 7.4, 10 mM NaCl, 150 mM 
KCl, 2.5 mM MgCl2) with the appropriate amount of [3H]-labeled arginine and cold argine. 
At the end of one hour, the beads were aspirated dry and rapidly washed three times with 
cytosolic buffer. The beads were aspirated dry again and resuspended in 85 μl of cytosolic 
buffer. Each sample was mixed well and three 10 μl aliquots were separately quantified 
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using a TriCarb scintillation counter (PerkinElmer). This process was repeated in pairs for 
each sample, to ensure similar incubation and wash times for all samples analyzed across 
different experiments.
In vitro CASTOR1-GATOR2 dissociation assay with arginine analogues
HEK-293T were transfected with HA-CASTOR1 constructs as described above. 48 hours 
after transfection, cells were starved for all amino acids for 50 minutes, lysed and subjected 
to anti-FLAG immunoprecipitation as described previously. The CASTOR1-GATOR2 
complexes immobilized on the HA beads were washed twice in lysis buffer with 500 mM 
NaCl, then incubated for 20 minutes in 1 mL of cytosolic buffer with 400 μM of the 
indicated compound. The amount of GATOR2 and CASTOR1 that remained bound was 
assayed by SDS-PAGE and immunoblotting as described previously.
Cell lines and tissue culture
HEK-293T cells were maintained at 37°C and 5% CO2 and cultured in DMEM 10% IFS 
supplemented with 2 mM glutamine, penicillin (100 IU/ml) and streptomycin (100 μg/ml). 
HEK-293T cells were obtained from the American Type Culture Collection (ATCC) and 
were free of mycoplasma contamination.
Statistical analysis
For the arginine-binding assays, two-tailed t tests were used for comparison between two 
groups. All comparisons were two-sided, and P values of less than 0.005 were considered to 
indicate statistical significance. The data meet the assumptions of the test and the variance is 
similar between groups that are being statistically compared.
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Extended Data
Extended Data Figure 1. Multiple sequence alignment of CASTOR1 homologues
a) Expanded Multiple Sequence Alignment of CASTOR1 homologues from various 
organisms. Positions are colored white to blue according to increasing sequence identity. 
Secondary structure features are labeled and colored by ACT domain as in 1A.
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Extended Data Figure 2. Dimerization deficient CASTOR1 mutants bind arginine but fail to 
inhibit mTORC1 in cells
a) The dimerization deficient CASTOR1 Y207S and I202E mutants bind arginine in vitro. 
FLAG-immunoprecipitates prepared from HEK-293T cells transiently expressing indicated 
FLAG-tagged proteins were used in binding assays with [3H]Arginine as described in the 
methods. Unlabeled arginine was included as a competitor where indicated. Values are Mean 
± SD for 3 technical replicates from one representative experiment.
b) Dimerization deficient CASTOR1 Y207S and I202E mutants fail to inhibit mTORC1. 
HEK-293T cells transiently expressing FLAG-S6K1 and HA-tagged CASTOR1 WT, 
Y207S, or I202E were starved of arginine for 50 min and, where indicated, restimulated for 
10 min. FLAG- immunoprecipitates were prepared from lysates and analyzed as in 1C. 
Phospho-S6K1 was used as an indicator of mTORC1 activity.
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Extended Data Figure 3. Model of lysine-binding in CASTOR1
a) Comparison of the arginine-bound pocket of human CASTOR1 with a model of the 
pocket with lysine in place of arginine. Arginine and lysine stick representations are shown 
in yellow and orange, respectively. The distances in the lysine-bound model, 3.8 Å and 5.0 
Å, are beyond the range of standard hydrogen-bonds and salt-bridges, respectively. ACT 
domains are labeled as in 1A.
b) Chemical structures of arginine analogues used in Fig. 2E. Differences relative to L-
Arginine are highlighted in oranges boxes.
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Extended Data Figure 4. Differences in the arginine-binding capacities of CASTOR1 and 
CASTOR2
a) Multiple sequence alignment of human CASTOR1 and CASTOR2, highlighting 
differences in amino acid sequence that are in close proximity to arginine binding residues in 
CASTOR1.
b) The CASTOR1 HHV108–110QNI mutant constitutively binds GATOR2 in cells. 
HEK-293T cells transiently expressing HA-metap2 or the indicated HA-tagged CASTOR1 
constructs were starved of arginine for 50 min and, where indicated, restimulated for 10 min. 
HA-immunoprecipitates prepared and analyzed as in 1C.
c) The CASTOR1 HHV108–110QNI mutant displays reduced arginine-binding capacity in 
vitro. Binding assays were performed with the indicated CASTOR1 or CASTOR2 constructs 
and immunoprecipitates analyzed as in 2C. Values are Mean ± SD for 3 technical replicates 
from one representative experiment.
d) Comparison of the CASTOR1 HHV108–110QNI mutant and WT CASTOR2. HEK-293T 
cells transiently expressing HA-metap2 or the indicated HA-tagged CASTOR1 or 
CASTOR2 constructs were starved of arginine for 50 min and, where indicated, restimulated 
for 10 min. HA-immunoprecipitates prepared and analyzed as in 1C.
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Extended Data Figure 5. GATOR2-binding deficient CASTOR1 mutants still bind arginine and 
homodimerize
a) The CASTOR1 YQ118–119AA, D121A, E261A and D292A mutants bind arginine in 
vitro. FLAG-immunoprecipitates prepared from HEK-293T cells transiently expressing 
indicated FLAG-tagged proteins were used in binding assays with [3H]Arginine as described 
in the methods. Unlabeled arginine was included as a competitor where indicated. Values are 
Mean ± SD for 3 technical replicates from one representative experiment.
b) The CASTOR1 YQ118–119AA, D121A, E261A and D292A mutants dimerize in cells. 
HA-immunoprecipitates prepared from HEK293T-cells transiently expressing CASTOR1-
FLAG and HA-metap2 or the indicated HA-tagged CASTOR1 constructs were analyzed as 
in 1C.
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Extended Data Figure 6. Similarities between human CASTOR1 and prokaryotic Aspartate 
Kinases
a) Ribbon diagram views of human CASTOR1 (this paper), AKeco (PDB ID: 2J0x) and 
AKsyn (PDB ID: 3L76), highlighting the different modes of dimerization. AKs can dimerize 
through an interlocked-ACT domain conformation (as in AKeco) or through their kinase 
domains (AKsyn), both of which are distinct from the side-by-side ACT-domain 
dimerization in CASTOR1.
b) View of AKeco depicting positions of residues R305, E346, and V347, which correspond 
to the positions of GATOR2-interacting residues of CASTOR1.
Extended Data Table 1
Data collection and refinement statistics (SAD)
CASTOR1 + Arg Native CASTOR1 + Arg SeMet
Organism H. sapiens H. sapiens
PDB ID 5I2C
Data collection
Space group P21 P21
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CASTOR1 + Arg Native CASTOR1 + Arg SeMet
Cell dimensions
 a, b, c (Å) 91.39, 82.60, 96.67 91.76, 82.35, 96.71
 α, β, γ (°) 90, 116.23, 90 90, 116.04, 90
Peak
Wavelength (Å) 0.9792 0.9792
Resolution (Å) 86.7 – 1.80 86.89 – 2.20
Rsym (%) 7.2 (62.8) 10.4 (>100)
I/σI 25.9 (1.2) 22.6 (1.4)
Completeness (%) 97.85 (87.1) 98.2 (98.1)
Redundancy 3 (2.5) 6.4 (5.9)
Anomolous Completeness (%) 96.8
Refinement
Resolution (Å) 86.71 – 1.80
No. reflections 116,883
Rwork/Rfree 17.2%/20.4%
No. atoms 9,872
 Protein 9,012
 Arg 48
 Water 796
Average B-factors (Å) 40.2
 Protein 40.0
 Arg 26.8
 Water 46.4
R.m.s. deviations
 Bond lengths (Å) 0.007
 Bond angles (°) 0.85
*Values in parentheses are for highest-resolution shell.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Architecture of human CASTOR1
a, Two orthogonal views of the CASTOR1 homodimer (ribbon diagram), with ACT-domains 
1–4 colored in green, purple, wheat, and pink, respectively. The bound arginine is shown in 
yellow. Disordered regions not observed in the crystal structure are omitted. b, View of the 
CASTOR1 dimerization interface, with side chains of key residues represented in stick form. 
c, Dimerization deficient CASTOR1 Y207S and I202E mutants display weaker interactions 
with endogenous GATOR2. HEK-293T cells transiently expressing FLAG-tagged 
CASTOR1 wild type (WT) and the indicated HA-tagged constructs were starved of arginine 
for 50 min and, where indicated, restimulated for 10 min. HA-immunoprecipitates were 
generated from cell lysates and analyzed by immunoblotting for the indicated proteins. Mios 
was used as a representative GATOR2 component.
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Figure 2. The arginine-binding pocket of CASTOR1
a, View of the arginine-binding pocket in CASTOR1, together with its Fo-Fc electron 
density map calculated and contoured at 4σ from an omit map lacking arginine. The bound 
arginine is shown in yellow. Hydrogen bonds or salt-bridges are shown as black dashed 
lines. Residues 269–273 are omitted for clarity. b, Steric view of the arginine-binding 
pocket, depicting the surface representation of CASTOR1 and stick model of arginine 
(yellow). The β14-loop (residues 269–280) is omitted for clarity. c, CASTOR1 S111A and 
D304A mutants do not bind arginine in vitro. FLAG-immunoprecipitates prepared from 
HEK-293T cells transiently expressing indicated FLAG-tagged proteins were used in 
binding assays with [3H]Arginine as described in the methods. Values are Mean ± SD for 3 
technical replicates from one representative experiment. d, The CASTOR1 S111A and 
D304A mutants constitutively bind GATOR2 and inhibit mTORC1 signaling in cells. 
HEK-293T cells transiently expressing FLAG-S6K1 and the indicated HA-tagged constructs 
were starved of arginine for 50 min and, where indicated, restimulated for 10 min. Both 
FLAG- and HA-immunoprecipitates were prepared from lysates and analyzed as in 1c. e, 
Effects of various arginine analogues on the CASTOR1-GATOR2 interaction in vitro. 
HEK-293T cells transiently expressing HA-CASTOR1 WT were starved of arginine for 50 
min. HA-immunoprecipitates were prepared from cell lysates then incubated with 400 μM of 
the indicated compounds for 20 min and analyzed as in 1c.
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Figure 3. Arginine facilitates the intramolecular association of the ACT2 and ACT4 domains of 
CASTOR1
a, Top-down view of the arginine- and β14-loop-mediated contacts between ACT2 and 
ACT4. Hydrogen bonds and salt-bridges are shown as black dashed lines. b, CASTOR1 
D276A, R126A, E277A, H175A, and C278A mutants display reduced arginine-binding 
capacity in vitro. Binding assays were performed and immunoprecipitates analyzed as in 2c. 
Values are Mean ± SD for 3 technical replicates from one representative experiment. c, The 
CASTOR1 D276A, R126A, E277A, H175A, and C278A mutants constitutively bind 
GATOR2 in cells. HEK-293T cells transiently expressing the indicated HA-tagged 
constructs were starved of arginine for 50 min and, where indicated, restimulated for 10 min. 
HA-immunoprecipitates prepared and analyzed as in 1c. d, CASTOR1 ACT1–2 (1–169) and 
CASTOR1 ACT3–4 (169–329) associate in an arginine- and β14-loop dependent manner. 
HEK-293T cells transiently expressing the indicated HA-tagged constructs were starved of 
arginine for 60 min and, where indicated, restimulated for 60 min. HA-immunoprecipitates 
were prepared and analyzed as in 1c.
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Figure 4. The GATOR2 binding site of CASTOR1 is at the ACT2-ACT4 interface and is required 
for signalling arginine deprivation to mTORC1
a, The CASTOR1 D292A, E261A, D121A, and YQ118–119AA mutants are deficient in 
GATOR2 binding. HA-immunoprecipitates prepared from HEK293T-cells transiently 
expressing the indicated HA-tagged constructs were analyzed as in 1c. b, Solvent-exposed 
surface view of the CASTOR1 homodimer highlighting the GATOR2-binding sites (red). 
Residue E261 is in a partially disordered loop and not visible in one monomer (left). c, 
Cross-sectional view of the ACT2-ACT4 interface showing the positions of the critical 
GATOR2-binding residues relative to the bound arginine (yellow) and the β14-loop. d, The 
GATOR2-binding-deficient YQ118–119AA and D121A mutants of CASTOR1 fail to inhibit 
the mTORC1 pathway and render cells insensitive to arginine starvation. HEK-293T cells 
were transiently transfected with FLAG-S6K1 and the indicated HA-tagged constructs. 
FLAG-immunoprecipitates were prepared and analyzed as in 1d. e, Model of how arginine 
releases CASTOR1 from GATOR2 to activate mTORC1.
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Figure 5. Insights into the evolution of arginine sensing by CASTOR1
a, (Top) Ribbon view of human CASTOR1 dimer (pink and purple) and AKeco dimer (blue 
and yellow, PDB ID 2J0X). (Bottom) Ribbon view of the human CASTOR1 monomer (left) 
and regulatory domain from AKeco (right). b, Comparison of the arginine-binding pocket in 
human CASTOR1 with the lysine-binding pocket in AKeco. Arginine and lysine are shown 
in yellow and orange, respectively. Hydrogen bonds and salt-bridges are shown as black 
dashed lines. c, Phylogenetic distribution of Aspartate Kinase (orange) and CASTOR1 
homologues (purple). d, Model of the evolution of CASTOR1 from the regulatory domain of 
an ancestral Aspartate Kinase.
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